Roberta Angelico, Silvia Trapani, Michele Colledan, Umberto Cillo, Tullia Maria De Feo, Marco Spada – 19 February 2018
Bradley Reuter, Kara Walter, Julien Bissonnette, Michael D. Leise, Jennifer Lai, Puneeta Tandon, Patrick S. Kamath, Scott W. Biggins, Christopher F. Rose, James B. Wade, Jasmohan S. Bajaj – 19 February 2018 – Hepatic encephalopathy (HE) is a major cause of morbidity in cirrhosis. However, its severity assessment is often subjective, which needs to be studied systematically. The aim was to determine how accurately trainee and nontrainee practitioners grade and manage HE patients throughout its severity.
Peter T. W. Kim, Goran B. Klintmalm – 16 February 2018
Xiao‐Jing Zhang, Zhi‐Gang She, Hongliang Li – 16 February 2018
Quirino Lai, Alessandro Vitale – 16 February 2018
Ka Wing Ma, Kenneth Siu Ho Chok, Wong Hoi She, Albert Chi Yan Chan, Tan To Cheung, Wing Chiu Dai, James Yan Yue Fung, Chung Mau Lo – 16 February 2018 – Salvage liver transplantation (sLT) and repeated resection (RR) are effective treatments for recurrent hepatocellular carcinoma (HCC), and comparisons of the oncological outcomes between these 2 modalities were scarce. Consecutive patients admitted for either sLT or RR for recurrent HCC were recruited. All patients in the present series received either prior hepatectomy, ablative therapy, or both before RR or sLT.
Acute on chronic liver failure is increasingly understood in adults, less so in children. The aims of this Webinar are to increase understanding about the causes of acute liver decompensation in children with chronic, compensated liver disease, and the acute-care management of ACLF.John Bucuvalas (Moderator) John Bucuvalas MD, FAASLD is Professor of Pediatrics and has a broad background in transplant hepatology.
Wei Zhu, Yibing Peng, Lan Wang, Yuan Hong, Xiaotao Jiang, Qi Li, Heping Liu, Lei Huang, Juan Wu, Esteban Celis, Todd Merchen, Edward Kruse, Yukai He – 14 February 2018 – Hepatocellular carcinoma (HCC) is the major form of liver cancer for which there is no effective therapy. Genetic modification with T‐cell receptors (TCRs) specific for HCC‐associated antigens, such as α‐fetoprotein (AFP), can potentially redirect human T cells to specifically recognize and kill HCC tumor cells to achieve antitumor effects.
Naga Chalasani, on behalf of the Writing Group for the AASLD NAFLD Practice Gudiance – 14 February 2018
William Carey – 14 February 2018